LifeStance Health Group, Inc. — Q3 2026 Earnings Summary

Financial Performance:

• Total revenue for Q3 2026 was $455.9 million, a 25% increase year-over-year from $363.8 million.
• Net income for Q3 2026 was $22.4 million, compared to $1.1 million in the prior-year period.
• Adjusted EBITDA for Q3 2026 was $68.4 million, a 70% increase from $40.2 million in Q3 2025, representing 15.0% of total revenue.
• Center Margin for Q3 2026 was $161.4 million, a 38% increase from $116.6 million in Q3 2025, representing 35.4% of total revenue.
• Income from operations for Q3 2026 was $33.1 million, compared to $7.4 million in Q3 2025.
• Net cash provided by operating activities for the nine months ended September 30, 2026, was $170.0 million.
• Free cash flow generation for the third quarter was $22.4 million.
• Net long-term debt stood at $255.5 million as of September 30, 2026.
• Cash and cash equivalents were $218.8 million as of September 30, 2026.
• For the nine months ended September 30, 2026, total revenue was $1,294.7 million compared to $1,042.1 million in the prior year.

Guidance and Future Outlook:

• Full-year 2026 revenue guidance raised to $1.741 billion to $1.761 billion.
• Full-year 2026 Center Margin guidance raised to $599 million to $613 million.
• Full-year 2026 Adjusted EBITDA guidance raised to $242 million to $250 million.
• Fourth quarter 2026 revenue guidance is $446 million to $466 million.
• Fourth quarter 2026 Center Margin guidance is $149 million to $163 million.
• Fourth quarter 2026 Adjusted EBITDA guidance is $56 million to $64 million.

Business Segments and Product Lines:

• The clinician base increased 11% year-over-year to 8,863 clinicians, with a sequential net increase of 321 in the third quarter.
• Third quarter visit volumes increased 17% to 2.7 million.
• Revenue growth was driven by higher visit volumes from net clinician growth, improved clinician productivity, and higher total revenue per visit.
• Positive patient outcomes were noted, specifically across TMS and Spravato treatments.
• The company is implementing a new Electronic Health Record (EHR) system.
• The company operates across 35 states and more than 575 centers.

Market and Competitive Landscape:

• LifeStance is identified as one of the nation's largest providers of outpatient mental healthcare.
• The company serves children, adolescents, and adults with various mental health conditions.
• The industry is described as heavily regulated and competitive.

Risks and Challenges:

• Risks include potential reductions in reimbursement rates by third-party payors or restrictions on care delivery.
• Challenges include the ability to recruit and retain clinicians and successfully execute growth initiatives.
• Regulatory compliance risks exist due to the heavily regulated nature of the industry.
• The business relies on relationships with supported practices which are not owned by the company.
• Risks related to data security breaches and the integrity of information technology systems are noted.
• Existing indebtedness could adversely affect business and growth prospects.

Management Commentary and Tone:

• CEO Dave Bourdon stated the team delivered a "tremendous quarter" with execution exceeding expectations.
• Management expressed confidence in raising the full-year outlook due to strong momentum.
• Management highlighted investments in the platform, specifically the new EHR implementation, as positioning the company for long-term success and scale.
• Management noted improved operating leverage as revenue grew faster than general and administrative expenses.

Other Key Points:

• The company repurchased common stock totaling $122.4 million during the nine months ended September 30, 2026.
• Acquisitions of businesses, net of cash acquired, totaled $9.6 million for the nine months ended September 30, 2026.
• Purchases of property and equipment were $37.4 million for the nine months ended September 30, 2026.
• A loss on remeasurement of contingent consideration of $2.3 million was recorded in Q3 2026.
• Strategic initiatives expenses related to the EHR implementation totaled $1.7 million in Q3 2026 and $2.7 million for the nine months ended September 30, 2026.
• Transaction costs of $0.5 million were recorded in Q3 2026 and $1.5 million for the nine months ended September 30, 2026.
• The company holds a conference call on November 5, 2026, at 8:30 a.m. Eastern Time.